ReviewAmerican journal of translational research2025
Efficacy and safety of Guanxin Danshen dropping pills for the treatment of angina pectoris: a meta-analysis.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combined use of clopidogrel and atorvastatin for angina pectoris caused by coronary heart disease: clinical effectiveness, safety, and contributing factors.American journal of translational research · 2026Article
- Overview of systematic reviews on Chinese patented oral medicines for promoting blood circulation and removing blood stasis combined with western medicine in the treatment of coronary heart disease angina pectoris.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the effect of Guanxin Danshen dropping pills (GDDP) for treating angina pectoris (AP) in patients with coronary heart disease (CHD).
methodsRandomized controlled trials (RCTs) evaluating GDDP for AP in CHD patients were systematically screened from PubMed, Cochrane Library, Web of Science, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WanFang databases from database inception to March 2023. Bias assessment followed the Cochrane Manual 5.1 criteira, and data analysis was performed using RevMan 5.3.
resultsTwenty articles were included in the meta-analysis. Compared to standard therapy, GDDP exhibited a superior efficacy in treating AP (P < 0.01), significantly improved electrocardiogram (ECG) outcomes in AP patients (P < 0.00001), reduced frequency of AP episodes (P < 0.01), lowered incidence of cardiovascular events in AP patients (P = 0.01) and significantly elevated hypersensitive C-reactive protein (hs-CRP) and interleukin-18 (IL-18) levels (all P < 0.01). However, it did not significantly affect the levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), or matrix metalloproteinase-9 (MMP-9) (all P > 0.05). GDDP also reduced total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels (all P < 0.01) as well as whole blood viscosity (WBV), plasma viscosity, fibrinogen and hematocrit levels (all P < 0.01). Additionally, the combination of GDDP and conventional CHD treatment was found to be safe.
conclusionCombining GDDP with conventional western medicine was more effective than either treatment alone in reducing cardiovascular events, alleviating angina symptoms, improving inflammation, and optimizing hemorheological parameters, without increasing side effects. These findings underscore GDDP's use as a complementary treatment for CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.